Abbott RealTime IDH2
Abbott Molecular, Inc. · Decision date May 28, 2026
What did the FDA decide?
FDA records P170005/S006 as a supplement to PMA P170005, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 28, 2026.
FDA approval order statement
implementation of manufacturing changes
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Medical Genetics
- Decision date
- May 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P170005/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Molecular, Inc.
- Product code
- OWD
- Decision code
- OK30
- Decision date
- May 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- Abbott Molecular, Inc.
- Product code
- OWD
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170005/S005 · Related supplement
Abbott RealTime IDH2
P170005/S006 received
Application receipt date recorded by FDA.
P170005/S006 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P170005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Abbott RealTime IDH2P170005/S005 | Abbott Molecular, Inc. | PMA supplement | Mar 20, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Molecular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1300 E Touhy Ave., Des Plaines, IL, 60018
Sources and methodology
- Original FDA record: P170005/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




